Patient deaths halt study of new approach to treating cancer (experimental drug JCAR015/others)

Patient deaths halt study of new approach to treating cancer

 With the two new deaths, Juno faces tough questions about the safety of its therapy, called JCAR015. And the FDA will likely come under fire for allowing the company to get back to work just days after the first clinical hold.

 JUNO: https://www.junotherapeutics.com/pipeline/clinical/

 MUC16

JCAR020

NCT02498912

A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

clinicaltrials.gov:

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This study is currently recruiting participants. (see Contacts and Locations)

Verified November 2016 by Memorial Sloan Kettering Cancer Center

Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

Stanford University

Juno Therapeutics, Inc.

Information provided by (Responsible Party):

Memorial Sloan Kettering Cancer Center